Ann: CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation, page-4

I wonder if this is their way of presenting the Cohort 3 results to the public as all of PH's companies like to follow the Playbook and release info at major conferences.

Interesting that JC says will have top line 1101 data for all of GMB trial by end of the year.

Just judging from Kerry's reaction, CHM is most definitely not even close to being on people's radar. Also knew that the new asset naming convention adopted would confuse people new to the story.

Hope this can spark some interest and hopefully not matched by more continued selling.